Genetic Testing and Adverse Selection in the Market for Life Insurance
The human genome project is rapidly fueling the development of genetic tests for inherited diseases. Over 100 different genetic tests are currently available for a wide range of diseases including Huntington disease, hypercholesterolemia, sickle-cell trait, and selected forms of Alzheimer’s disease, colon cancer, melanoma, breast and ovarian cancer. The U.S. Congressional Office of Technology Assessment has projected that there will be a tenfold rise in the number of genetic tests that are available during the 1990s (U.S. Congressional..., 1988). Increasingly, a variety of public and private interest groups are raising questions about what individuals and society should do with such genetic information. Within the life and health insurance markets, ethical concerns regarding genetic discrimination are clashing with the underwriting needs of insurance companies.
KeywordsOvarian Cancer Genetic Test Life Insurance Adverse Selection Genetic Test Result
Unable to display preview. Download preview PDF.
- American Council of Life Insurance (1994), ‘The need for genetic information in risk classification’, Washington, DC.Google Scholar
- Billings, P.R. cited in Chase, D. (1992), ‘In the battle over genetic testing, critics must be reconed with’, Council Review, vol. 17:9–10.Google Scholar
- Cawley J. and Philipson, T. (1996), ‘An empirical examination of information barriers to trade in insuarnce’, working paper, University of Chicago.Google Scholar
- Council for Responsible Genetics (1995), Testimony to the National Association of Insurance Commissioners’ Genetic Testing Working Group, March 12.Google Scholar
- Council of State Governments (1993), Advances in genetic information — A guide for state policy makers, Iron Works Pike: Lexington, KY.Google Scholar
- Frank, R.G. and McGuire, T.G. (1986), ‘Adverse selection in insurance markets: A selective survey’, in Dionne, G. (ed.), Contributions to Insurance Economics, Kluwer Academic Publishers: Boston, MA, pp. 97–140.Google Scholar
- Haney, D.Q. (1997), ‘Double mastectomy radical, effective’, Wisconsin State Journal, April 14, p. 1A.Google Scholar
- McGoodwin, W. (1997), ‘Biotechnology and the consumer.’ Esther Peterson Consumer Policy Forum Speech at the American Council on Consumer Interests’ annual conference, April 5, and forthcoming in The Journal of Consumer Affairs.Google Scholar
- National Association of Insurance Commissioners (1996), Report of the Genetic Testing Working Group to the Life Insurance (A) Committee, June.Google Scholar
- U.S. Congressional Office of Technology Assessment (1988), Mapping our genes: How big, how fast? OTA-BA-373, U.S. Government Printing Office: Washington DC.Google Scholar
- Zick, CD. and Mayer, R.M. (1996), ‘Consumption in the land of milk and (home-baked) cookies’, in Heaton, T.B., Hirschl, T.A., and Chadwick, B. (eds.) Utah in the 1990s — A demographic perspective, Signature Books: Salt Lake City, UT, pp. 139–154.Google Scholar